Drug Products: Biologics, Biosimilars and Interchangeables

Biologics originate from living sources like humans, animals, or microorganisms. They are developed using biotechnology or purified from natural sources, with insulin and growth hormones being well-known examples.

The Patient Protection and Affordable Care Act of 2010 has established a regulatory approval pathway for generic versions of biologics, such as interchangeable and biosimilar products.

Biosimilar products are highly similar to the reference product, with no clinically meaningful differences in safety, purity, and potency.

In contrast, interchangeable products are interchangeable with the reference product and produce the same clinical result as the reference product without increased risk or diminished efficacy.

Biosimilarity assessment involves robust characterization, including comparative physicochemical and functional studies. Factors such as manufacturing processes, receptor binding properties, immunochemical properties, impurity identification, and stability should also be assessed.

FDA determination relies on evidence provided by sponsors, employing analytical, animal, and clinical studies to demonstrate safety, purity, and potency.